Impact of dyslipidemia and lipid‐lowering therapy with statins in patients with neuroendocrine tumors
Journal of Neuroendocrinology · 2025
DOI: 10.1111/jne.13485 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Neuroendocrinology, 2025. Verfasst von Antongiulio Faggiano und 22 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, Department of Clinical and Molecular Medicine, European Neuroendocrine Tumor Society (ENETS) Center of Excellence, Sant'Andrea Un…. Hauptthemen laut MEDLINE: Dyslipidemias, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Neuroendocrine Tumors, Pancreatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
Dyslipidemia is a potential unfavorable prognostic factor in neuroendocrine tumors (NETs); conversely, statins proved to have antiproliferative effects in NET cell lines and could be a helpful therapeutic strategy for these patients. The main objective of this observational cohort retrospective study is to explore the associations between dyslipidemia and NET progression and evaluate the potential influence of statins in this context. 393 patients with histologically confirmed gastroenteropancreatic or bronchopulmonary NETs from six Italian centres didicated to NET diagnosis and therapy were included. The cohort included 123 patients with dyslipidemia, 81 of which were taking statins. Clinicopathological data, including patient demographics, tumor characteristics, and treatment details as well as the prevalence, timing of dyslipidemia and hypolipemic therapy were collected. The main outcome measure used is progression‐free survival (PFS). Among the 393 patients, 123 (31.3%) had dyslipidemia. Statins were used by 81 (65.8%) dyslipidemic patients, mostly atorvastatin. Median PFS was 87 months overall, 124 months in non‐dyslipidemic patients, and 72 months in dyslipidemic patients ( p = .268). Dyslipidemic patients on statins had a significantly better median PFS (108 months) than those not on statins (26 months; p = .024). Recurrence‐free survival (RFS) was also evaluated, but no significant differences were found. In conclusion, while PFS was lower in dyslipidemic patients compared to non‐dyslipidemic patients, the difference was not statistically significant. Statin therapy was associated with improved PFS among dyslipidemic patients, suggesting a potential antiproliferative effect of statins in NETs. These findings warrant further investigation to substantiate the role of statins in the management of NETs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology Unit, Department of Clinical and Molecular Medicine, European Neuroendocrine Tumor Society (ENETS) Center of Excellence, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
- Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
- Oncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
- Endocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
- Endocrinology Unit, Department of Clinical and Experimental Medicine, Garibaldi - Nesima Medical Center, University of Catania, Catania, Italy.
- Department of Human Pathology of Adulthood and Childhood 'G. Barresi', University of Messina, Messina, Italy.
ORCID-Profile: Antongiulio Faggiano, Flaminia Russo, Roberta Modica, Rosa Lauretta, Antonio Prinzi, Francesco Panzuto, Annamaria Colao
Förderung
- Ministero della Salute
Zitieren
APA
Faggiano, A., Russo, F., Zamponi, V., Sesti, F., Puliani, G., Modica, R., Malandrino, P., Ferraù, F., Rinzivillo, M., Di Muzio, M., Di Simone, E., Panattoni, N., Dolce, P., Lauretta, R., Di Iasi, G., Prinzi, A., Alessi, Y., Feola, T., Mazzilli, R., …, & Colao, A. (2025). Impact of dyslipidemia and lipid‐lowering therapy with statins in patients with neuroendocrine tumors. Journal of Neuroendocrinology. https://doi.org/10.1111/jne.13485
Vancouver
Faggiano A, Russo F, Zamponi V, Sesti F, Puliani G, Modica R, et al. Impact of dyslipidemia and lipid‐lowering therapy with statins in patients with neuroendocrine tumors. Journal of Neuroendocrinology. 2025. doi:10.1111/jne.13485
BibTeX
@article{Faggiano2025,
author = {Faggiano, Antongiulio and Russo, Flaminia and Zamponi, Virginia and Sesti, Franz and Puliani, Giulia and Modica, Roberta and Malandrino, Pasqualino and Ferraù, Francesco and Rinzivillo, Maria and Di Muzio, Marco and Di Simone, Emanuele and Panattoni, Nicolò and Dolce, Pasquale and Lauretta, Rosa and Di Iasi, Gianfranco and Prinzi, Antonio and Alessi, Ylenia and Feola, Tiziana and Mazzilli, Rossella and Appetecchia, Marialuisa and Giannetta, Elisa and Panzuto, Francesco and Colao, Annamaria},
title = {Impact of dyslipidemia and lipid‐lowering therapy with statins in patients with neuroendocrine tumors},
journal = {Journal of Neuroendocrinology},
year = {2025},
doi = {10.1111/jne.13485}
}
EUVIMED